Compass Pathways (NASDAQ:CMPS) Shares Up 9.8% – Should You Buy?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS)’s stock price was up 9.8% during mid-day trading on Wednesday . The company traded as high as $13.20 and last traded at $12.96. 3,254,767 shares were traded during trading, a decline of 13% from the average session volume of 3,720,214 shares. The stock had previously closed at $11.80.

Analyst Upgrades and Downgrades

CMPS has been the topic of several research analyst reports. BTIG Research boosted their price objective on shares of Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Maxim Group increased their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. UBS Group set a $18.00 price target on shares of Compass Pathways in a research report on Thursday, May 7th. Compass Point set a $25.00 price target on shares of Compass Pathways in a research note on Tuesday, July 7th. Finally, Canaccord Genuity Group upped their price objective on shares of Compass Pathways from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Price Performance

The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The stock has a 50 day moving average price of $12.51 and a two-hundred day moving average price of $9.22. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -4.25 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Institutional Trading of Compass Pathways

A number of institutional investors and hedge funds have recently bought and sold shares of CMPS. Corient Private Wealth LLC boosted its stake in shares of Compass Pathways by 3.2% in the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after purchasing an additional 1,200 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares in the last quarter. Conservest Capital Advisors Inc. increased its stake in Compass Pathways by 24.6% during the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock worth $175,000 after buying an additional 5,000 shares during the period. Persistent Asset Partners Ltd purchased a new stake in Compass Pathways during the 4th quarter worth approximately $38,000. Finally, Raymond James Financial Inc. lifted its holdings in Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after buying an additional 6,228 shares in the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.